Tackling inequalities in cancer care in the European Union IQN Path contributed to the report published by the IHE – The Swedish Institute for Health Economics with an insight on access to biomarker testing and precision medicine in Europe. Read it here: https://ihe.se/en/rapport/tackling-inequalities-in-cancer-care-in-the-european-union-2/
Category Archives: Uncategorized
New paper in European Journal of Cancer: “Access and quality of biomarker testing for precision oncology in Europe”
Abstract Background Predictive biomarkers are essential for selecting the best therapeutic strategy in patients with cancer. The International Quality Network for Pathology, the European Cancer Patient Coalition and the European Federation of Pharmaceuticals Industries and Associations evaluated the access to and quality of biomarker testing across Europe. Methods Data sources included surveys of 141 laboratory managers and read more…
NordiQC EQA Data and Observations for PD-L1 Biomarker Testing
NordiQC EQA Data and Observations for PD-L1 Biomarker Testing By Søren Nielsen, Director, NordiQC Immune-checkpoint inhibitors targeting PD-1 or PD-L1 as pembrolizumab, nivolumab, durvalumab and atezolizumab have since 2016 been approved for multiple cancers as lung carcinoma, urothelial carcinoma, melanoma, breast carcinoma and many other solid cancers. At present Immunohistochemistry (IHC) for PD-L1 expression is read more…
Unlocking the potential of precision medicine in Europe – Improving cancer care through broader access to quality biomarker testing
Advances in biomarker testing are having a transformative impact on cancer care, but Europe will have to overcome significant barriers in the equitable access and quality of these tests to realise their full potential, concludes an important new study released by the International Quality Network for Pathology (IQN Path), the European Cancer Patient Coalition (ECPC) and the read more…
IQN Path / EFPIA aim to raise awareness about biomarker testing in Europe and develop policy recommendations to improve access and quality
The project, launched in November 2019, was carried out throughout 2020, sometimes slowing the development, but steadily progressing, and will yield outstanding results that we are looking forward to sharing with you toward the end of February. The study was carefully devised and produced detailed results based on sound data collected from all stakeholders. We read more…
Our Experience during the Covid-19 Pandemic, by IQNPath Board Member Jingxin Qiu
Jingxin Qiu, Roswell Park Comprehensive Cancer Center, Buffalo, New York I’d first like to share a bit of background about our center. Roswell Park Comprehensive Cancer Center was established by Dr. Roswell Park in 1898 in Buffalo, New York — the first institution in the world to focus exclusively on cancer research. Over the years, Roswell read more…
Proficiency testing CBQA Readout
An academic proficiency testing program for the assessment of pathologists’ and technologists’ accuracy of biomarker readout IQN Path is pleased announce and endorse CBQAReadout.com. CBQAReadout.com (www.cbqareadout.ca) is a new proficiency testing (PT) program for pathologists’ readouts. The primary focus of this new PT program are predictive immunohistochemistry biomarkers such as PD-L1. In the future, the read more…